Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87% Market Closed
Market Cap: 11.2B SEK
Have any thoughts about
Calliditas Therapeutics AB?
Write Note

Intrinsic Value

The intrinsic value of one CALTX stock under the Base Case scenario is 744.65 SEK. Compared to the current market price of 208 SEK, Calliditas Therapeutics AB is Undervalued by 72%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CALTX Intrinsic Value
744.65 SEK
Undervaluation 72%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Calliditas Therapeutics AB

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CALTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CALTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Calliditas Therapeutics AB

Provide an overview of the primary business activities
of Calliditas Therapeutics AB.

What unique competitive advantages
does Calliditas Therapeutics AB hold over its rivals?

What risks and challenges
does Calliditas Therapeutics AB face in the near future?

Has there been any significant insider trading activity
in Calliditas Therapeutics AB recently?

Summarize the latest earnings call
of Calliditas Therapeutics AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Calliditas Therapeutics AB.

Provide P/S
for Calliditas Therapeutics AB.

Provide P/E
for Calliditas Therapeutics AB.

Provide P/OCF
for Calliditas Therapeutics AB.

Provide P/FCFE
for Calliditas Therapeutics AB.

Provide P/B
for Calliditas Therapeutics AB.

Provide EV/S
for Calliditas Therapeutics AB.

Provide EV/GP
for Calliditas Therapeutics AB.

Provide EV/EBITDA
for Calliditas Therapeutics AB.

Provide EV/EBIT
for Calliditas Therapeutics AB.

Provide EV/OCF
for Calliditas Therapeutics AB.

Provide EV/FCFF
for Calliditas Therapeutics AB.

Provide EV/IC
for Calliditas Therapeutics AB.

Show me price targets
for Calliditas Therapeutics AB made by professional analysts.

What are the Revenue projections
for Calliditas Therapeutics AB?

How accurate were the past Revenue estimates
for Calliditas Therapeutics AB?

What are the Net Income projections
for Calliditas Therapeutics AB?

How accurate were the past Net Income estimates
for Calliditas Therapeutics AB?

What are the EPS projections
for Calliditas Therapeutics AB?

How accurate were the past EPS estimates
for Calliditas Therapeutics AB?

What are the EBIT projections
for Calliditas Therapeutics AB?

How accurate were the past EBIT estimates
for Calliditas Therapeutics AB?

Compare the revenue forecasts
for Calliditas Therapeutics AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Calliditas Therapeutics AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Calliditas Therapeutics AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Calliditas Therapeutics AB compared to its peers.

Compare the P/E ratios
of Calliditas Therapeutics AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Calliditas Therapeutics AB with its peers.

Analyze the financial leverage
of Calliditas Therapeutics AB compared to its main competitors.

Show all profitability ratios
for Calliditas Therapeutics AB.

Provide ROE
for Calliditas Therapeutics AB.

Provide ROA
for Calliditas Therapeutics AB.

Provide ROIC
for Calliditas Therapeutics AB.

Provide ROCE
for Calliditas Therapeutics AB.

Provide Gross Margin
for Calliditas Therapeutics AB.

Provide Operating Margin
for Calliditas Therapeutics AB.

Provide Net Margin
for Calliditas Therapeutics AB.

Provide FCF Margin
for Calliditas Therapeutics AB.

Show all solvency ratios
for Calliditas Therapeutics AB.

Provide D/E Ratio
for Calliditas Therapeutics AB.

Provide D/A Ratio
for Calliditas Therapeutics AB.

Provide Interest Coverage Ratio
for Calliditas Therapeutics AB.

Provide Altman Z-Score Ratio
for Calliditas Therapeutics AB.

Provide Quick Ratio
for Calliditas Therapeutics AB.

Provide Current Ratio
for Calliditas Therapeutics AB.

Provide Cash Ratio
for Calliditas Therapeutics AB.

What is the historical Revenue growth
over the last 5 years for Calliditas Therapeutics AB?

What is the historical Net Income growth
over the last 5 years for Calliditas Therapeutics AB?

What is the current Free Cash Flow
of Calliditas Therapeutics AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Calliditas Therapeutics AB.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Calliditas Therapeutics AB

Current Assets 1.2B
Cash & Short-Term Investments 797.3m
Receivables 222.6m
Other Current Assets 134.6m
Non-Current Assets 592.7m
Long-Term Investments 27.2m
PP&E 59.4m
Intangibles 471.7m
Other Non-Current Assets 34.5m
Current Liabilities 429.8m
Accounts Payable 151m
Accrued Liabilities 252.1m
Other Current Liabilities 26.6m
Non-Current Liabilities 1.2B
Long-Term Debt 1B
Other Non-Current Liabilities 202.4m
Efficiency

Earnings Waterfall
Calliditas Therapeutics AB

Revenue
1.6B SEK
Cost of Revenue
-104.7m SEK
Gross Profit
1.5B SEK
Operating Expenses
-1.8B SEK
Operating Income
-353.1m SEK
Other Expenses
-127.2m SEK
Net Income
-480.4m SEK

Free Cash Flow Analysis
Calliditas Therapeutics AB

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q2 2024, revenues hit SEK 559.8 million, up from SEK 269.4 million last year. TARPEYO sales surged 90% to $46.3 million. Despite costs related to the Asahi Kasei offer, adjusted operating profit was SEK 70.2 million. Full approval in Europe for Kinpeygo and a new patent for the cancer treatment, setanaxib, bolstered prospects. The company raised its 2024 revenue guidance to $165-$185 million, indicating strong market demand. Operational cash flow improved, with a minimal net cash decrease and a strong position of SEK 797.3 million at quarter-end.

What is Earnings Call?
Fundamental Scores

CALTX Profitability Score
Profitability Due Diligence

Calliditas Therapeutics AB's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
33/100
Profitability
Score

Calliditas Therapeutics AB's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

CALTX Solvency Score
Solvency Due Diligence

Calliditas Therapeutics AB's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
43/100
Solvency
Score

Calliditas Therapeutics AB's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CALTX Price Targets Summary
Calliditas Therapeutics AB

Wall Street analysts forecast CALTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CALTX is 232.05 SEK with a low forecast of 178.77 SEK and a high forecast of 309.75 SEK.

Lowest
Price Target
178.77 SEK
14% Downside
Average
Price Target
232.05 SEK
12% Upside
Highest
Price Target
309.75 SEK
49% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CALTX?

Click here to dive deeper.

Dividends

Calliditas Therapeutics AB
does not pay dividends
Shareholder Yield

Current shareholder yield for CALTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CALTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB

Country

Sweden

Industry

Pharmaceuticals

Market Cap

11.2B SEK

Dividend Yield

0%

Description

Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Contact

STOCKHOLM
Stockholm
Kungsbron 1
+4684113005.0
www.calliditas.se

IPO

2018-06-29

Employees

65

Officers

Chief Executive Officer
Ms. Renee Aguiar-Lucander
Chief Financial Officer
Mr. Fredrik Johansson
Vice President of Technical Operations
Lars Stubberud
Head of IR & Sustainability
Ms. Asa Hillsten
Group General Counsel
Mr. Brian Gorman
Vice President of Human Resources
Ms. Sandra Frithiof
Show More
Head of Clinical Development & VP of Project Management
Ms. Ann-Kristin Myde BSc
Chief Medical Officer
Dr. Richard S. Philipson M.D.
Head of US Marketing
Ms. Teona Johnson
Head of US Sales
Mr. David Ferraro
Show Less

See Also

Discover More
What is the Intrinsic Value of one CALTX stock?

The intrinsic value of one CALTX stock under the Base Case scenario is 744.65 SEK.

Is CALTX stock undervalued or overvalued?

Compared to the current market price of 208 SEK, Calliditas Therapeutics AB is Undervalued by 72%.

Back to Top